Evidence map›Paper›PMID 24504023›Full record

ArticleLeukemia2014

Dual regulation of SPI1/PU.1 transcription factor by heat shock factor 1 (HSF1) during macrophage differentiation of monocytes.

G Jego, D Lanneau, A De Thonel, K Berthenet, A Hazoumé, N Droin, A Hamman, F Girodon, P-S Bellaye, G Wettstein and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. A Point Mutation in IKAROS ZF1 Causes a B Cell Deficiency in Mice.Journal of immunology (Baltimore, Md. : 1950) · 2021
    Article
  13. Article
  14. Article
  15. HSF1 as a Cancer Biomarker and Therapeutic Target.Current cancer drug targets · 2019
    Review
  16. Roles of heat shock factor 1 beyond the heat shock response.Cellular and molecular life sciences : CMLS · 2018
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 1 country.

G Jego1] INSERM, UMR 866, 'Equipe Labellisée Ligue contre le Cancer', Dijon, France [2] Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France.
D Lanneau1] INSERM, UMR 866, 'Equipe Labellisée Ligue contre le Cancer', Dijon, France [2] Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France.
A De Thonel1] INSERM, UMR 866, 'Equipe Labellisée Ligue contre le Cancer', Dijon, France [2] Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France.
K Berthenet1] INSERM, UMR 866, 'Equipe Labellisée Ligue contre le Cancer', Dijon, France [2] Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France.
A Hazoumé1] INSERM, UMR 866, 'Equipe Labellisée Ligue contre le Cancer', Dijon, France [2] Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France.
N Droin1] INSERM, UMR 1009, Institut Gustave Roussy, 114 rue Edouard Vaillaint, Villejuif, France [2] University Paris-Sud 11, Institut Gustave Roussy, 114 rue Edouard Vaillaint, Villejuif, France.
A Hamman1] INSERM, UMR 866, 'Equipe Labellisée Ligue contre le Cancer', Dijon, France [2] Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France.
F Girodon1] INSERM, UMR 866, 'Equipe Labellisée Ligue contre le Cancer', Dijon, France [2] Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France.
P-S Bellaye1] INSERM, UMR 866, 'Equipe Labellisée Ligue contre le Cancer', Dijon, France [2] Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France.
G Wettstein1] INSERM, UMR 866, 'Equipe Labellisée Ligue contre le Cancer', Dijon, France [2] Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France.
A Jacquel1] INSERM, UMR 866, 'Equipe Labellisée Ligue contre le Cancer', Dijon, France [2] Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France [3] INSERM, U526, Nice, France.
L Duplomb1] Faculty of Medicine and Pharmacy, Génétique et anomalies du développement, University of Burgundy, Dijon, France [2] CHU, Dijon, France.
A Le Mouël1] CNRS, UMR7216 Épigénétique et Destin Cellulaire, 35 rue Hélène Brion, Paris, France [2] University Paris Diderot, Sorbonne Paris Cité, 35 rue Hélène Brion, Paris, France.
C PapanayotouUniversity Paris Diderot, Sorbonne Paris Cité, Institut jacques Monod, UMR 7592, Paris cedex 13, France.
E ChristiansCNRS, UMR 5547, Université Paul Sabatier, 118 route de Narbonne, Toulouse, France.
P Bonniaud1] INSERM, UMR 866, 'Equipe Labellisée Ligue contre le Cancer', Dijon, France [2] Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France.
V Lallemand-Mezger1] CNRS, UMR7216 Épigénétique et Destin Cellulaire, 35 rue Hélène Brion, Paris, France [2] University Paris Diderot, Sorbonne Paris Cité, 35 rue Hélène Brion, Paris, France.
E Solary1] INSERM, UMR 1009, Institut Gustave Roussy, 114 rue Edouard Vaillaint, Villejuif, France [2] University Paris-Sud 11, Institut Gustave Roussy, 114 rue Edouard Vaillaint, Villejuif, France.
C Garrido1] INSERM, UMR 866, 'Equipe Labellisée Ligue contre le Cancer', Dijon, France [2] Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France [3] Centre de lutte contre le cancer George-François Leclerc, Dijon, France.
Centre de recherche Translationnelle en Médecine moléculaire · FRUniversité de Bourgogne · FRCentre de Biologie du Développement · FRCHU Dijon Bourgogne · FRContrôle transcriptionnel et épigénétique de l’hématopoïèse maligneEpigénétique et Destin Cellulaire · FRSorbonne Paris Cité · FRUniversité Paris Cité · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In addition to their cytoprotective role in stressful conditions, heat shock proteins (HSPs) are involved in specific differentiation pathways, for example, we have identified a role for HSP90 in macrophage differentiation of human peripheral blood monocytes that are exposed to macrophage colony-stimulating factor (M-CSF). Here, we show that deletion of the main transcription factor involved in heat shock gene regulation, heat shock factor 1 (HSF1), affects M-CSF-driven differentiation of mouse bone marrow cells. HSF1 transiently accumulates in the nucleus of human monocytes undergoing macrophage differentiation, including M-CSF-treated peripheral blood monocytes and phorbol ester-treated THP1 cells. We demonstrate that HSF1 has a dual effect on SPI1/PU.1, a transcription factor essential for macrophage differentiation and whose deregulation can lead to the development of leukemias and lymphomas. Firstly, HSF1 regulates SPI1/PU.1 gene expression through its binding to a heat shock element within the intron 2 of this gene. Furthermore, downregulation or inhibition of HSF1 impaired both SPI1/PU.1-targeted gene transcription and macrophage differentiation. Secondly, HSF1 induces the expression of HSP70 that interacts with SPI1/PU.1 to protect the transcription factor from proteasomal degradation. Taken together, HSF1 appears as a fine-tuning regulator of SPI1/PU.1 expression at the transcriptional and post-translational levels during macrophage differentiation of monocytes.

Indexed as

Cell DifferentiationAnimalsAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenCells, CulturedDNA-Binding ProteinsGene Expression RegulationHeat Shock Transcription FactorsHumansMacrophagesMiceMice, Inbred BALB CMice, Inbred C57BLMonocytesProteasome Endopeptidase ComplexAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenDNA-Binding ProteinsHeat Shock Transcription FactorsHSF1 protein, humanProteasome Endopeptidase ComplexProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Receptors, Cell SurfaceTrans-ActivatorsTranscription Factors

Identifiers

PMID24504023
OpenAlexW2029019156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.